Anzeige
Mehr »
Sonntag, 14.09.2025 - Börsentäglich über 12.000 News
Investment Idee: Einsteigen bevor sich die Schleuse öffnet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JWL4 | ISIN: NO0010598683 | Ticker-Symbol: HBQ
Frankfurt
12.09.25 | 21:40
0,138 Euro
-1,08 % -0,002
1-Jahres-Chart
HOFSETH BIOCARE ASA Chart 1 Jahr
5-Tage-Chart
HOFSETH BIOCARE ASA 5-Tage-Chart
RealtimeGeldBriefZeit
0,1380,18713.09.

Aktuelle News zur HOFSETH BIOCARE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiHofseth Biocare ASA: ProGo, the world's first consumer health GLP-1 & GIP receptor agonist with muscle mass protection via inhibition of Myostatin and Activin A pathways69HBC has today released a whitepaper demonstrating how its bioactive peptide ingredient ProGo® uniquely provides complete GLP-1 support. To maximize the effect of GLP-1 therapy, lean muscle mass needs...
► Artikel lesen
04.09.Hofseth Biocare ASA: HBC onboards former Head of Nestle Health Science Asia, Oceania, Middle East and Africa Region, Paul Bruhn9
HOFSETH BIOCARE Aktie jetzt für 0€ handeln
22.08.Hofseth Biocare ASA: Second Quarter 2025 Financial Report134HBC recorded total operating revenues of NOK 68.4 million in the second quarter of 2025, compared to NOK 80.4 million in the same period last year. Net operating revenues were NOK 67.8 million, compared...
► Artikel lesen
16.07.Hofseth Biocare ASA: HBC's ProGo has won Ingredient of the Year for Healthy Aging at the prestigious Nutraingredients USA awards ceremony in Chicago5
23.05.Hofseth Biocare ASA: Annual General Meeting completed1
16.05.Hofseth Biocare ASA: FIRST QUARTER 2025 FINANCIAL REPORT769HBC recorded total operating revenues of NOK 60.9 million in the first quarter of 2025, compared to NOK 52.4 million in the same period last year. Net operating revenues were NOK 60.7 million, reflecting...
► Artikel lesen
05.05.Hofseth Biocare ASA: NESTLÉ GARDEN OF LIFE LAUNCHES HBC OMEGO® FULL SPECTRUM OMEGAS IN THE US4
05.05.Hofseth Biocare ASA: SUCCESSFUL PLACEMENT OF NEW CHF-DENOMINATED UNSECURED BONDS2
02.05.Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 20253
11.04.Hofseth Biocare ASA: HBC ANNUAL REPORT 20246
21.02.Hofseth Biocare ASA: HBC Accelerates In Human Health And Pet Nutrition Through A Strategic Partnership With Symrise To Build Out Berkåk, Tripling The Manufacturing Capacity Of The Group526HBC will accelerate its manufacturing scale and market reach with the construction of a second enzymatic hydrolysis plant in Berkåk, Norway. Symrise will support the financing of the project through...
► Artikel lesen
14.02.Hofseth Biocare ASA: Fourth Quarter & Full Year 2024 Financial Report1.073HBC achieved full-year sales revenue of NOK 256.8 million, a 35% increase from 2023, with strong momentum in higher-margin B2B human nutrition. The shift towards premium products, particularly CalGo®...
► Artikel lesen
05.12.24Hofseth Biocare ASA: Commences the project for a second hydrolysis plant in Norway to triple capacity216Hofseth BioCare ASA ("HBC" or the "Company", and together with its consolidated subsidiaries, the "Group") is pleased to announce a Board resolution to start a project to build a second hydrolysis...
► Artikel lesen
08.11.24Hofseth Biocare ASA: Third Quarter 2024 Financial Report200HBC had gross operating revenues of NOK 67.9m (49.9m) in the third quarter and NOK 200.6m (171.1m) in the first nine months. The operating loss (EBITDA) for the quarter was NOK -21.0m (-16.2m) and NOK...
► Artikel lesen
14 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1